Publications by authors named "Kim Champion"
Article Synopsis
- The study evaluated the safety and effectiveness of using allodepleted donor T cells (ADTs) to enhance immune recovery in patients following matched unrelated donor (MUD) stem cell transplants, particularly after treatment with alemtuzumab for hematological cancers.
- Results showed a trend toward higher CD3+ T-cell counts at 4 months for those receiving ADTs compared to the control group, but the difference was not statistically significant, and a few patients achieved normal T-cell levels.
- While ADTs were deemed safe, the method's limited effect on T-cell reconstitution suggests it might be more beneficial in cases that involve more aggressive T-cell depletion.
Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled responses in relapsed/refractory acute lymphoblastic leukemia (ALL), but toxicity, including cytokine-release syndrome (CRS) and neurotoxicity, limits broader application. Moreover, 40-60% of patients relapse owing to poor CAR T cell persistence or emergence of CD19 clones. Some factors, including the choice of single-chain spacer and extracellular and costimulatory domains, have a profound effect on CAR T cell function and persistence.
View Article and Find Full Text PDFClinical trials are performed to discover or verify the efficacy and safety of one or more investigational medicinal product (IMP). Biological medicinal products, including gene therapies, offer groundbreaking new opportunities for the treatment of disease and injury, but they are also highly regulated and trials with these products can be logistically challenging to set up and execute. To ensure a compliant and successful trial, it is important to know and understand the regulatory framework, and to be aware of available guidance documents published to advise the different stakeholders on how to develop, manufacture, handle, administer, or destroy these products safely and legally.
View Article and Find Full Text PDFWe evaluated the role of granulocyte colony-stimulating factor (G-CSF) in patients with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine (CSA). Between January 2002 and July 2008, 192 patients with newly diagnosed SAA not eligible for transplantation were entered into this multicenter, randomized study to receive ATG/CSA with or without G-CSF. Overall survival (OS) at 6 years was 76% ± 4%, and event-free survival (EFS) was 42% ± 4%.
View Article and Find Full Text PDFPurpose: Although ovarian cancer is one of the most chemotherapy-sensitive solid tumors, cure after radical surgery and chemotherapy is uncommon. A randomized trial comparing high-dose sequential chemotherapy with peripheral blood stem cell (PBSC) support with platinum-based combination chemotherapy was conducted to investigate whether dose-intensification improves outcome.
Patients And Methods: One hundred forty-nine patients with untreated ovarian cancer were randomly assigned after debulking surgery to receive standard combination chemotherapy or sequential high-dose (HD) treatment with two cycles of cyclophosphamide and paclitaxel followed by three cycles of HD carboplatin and paclitaxel with PBSC support.